A changing treatment landscape for multiple sclerosis: challenges and opportunities
Article first published online: 16 MAR 2014
© 2014 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 275, Issue 4, pages 364–381, April 2014
How to Cite
(Karolinska Institutet, Stockholm, Sweden). A changing treatment landscape for multiple sclerosis: challenges and opportunities (Review). J Intern Med 2014; 275: 364–381.
- Issue published online: 25 MAR 2014
- Article first published online: 16 MAR 2014
- Accepted manuscript online: 20 JAN 2014 08:58AM EST
- biological therapies;
- immunomodulatory therapy;
- multiple sclerosis;
- randomized controlled trial
Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.